Clinical Research Directory
Browse clinical research sites, groups, and studies.
European Implementation Study on Simultaneous Screening for Gastric and Colorectal Cancers
Sponsor: University of Latvia
Summary
The EUGastScreen study is designed as a quality implementation study to explore gastric cancer screening strategies within organised cancer screening frameworks. The study is set to target individuals who are entering the age range for CRC screening, integrating gastric cancer screening into this existing structure.
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
OBSERVATIONAL
Enrollment
8000
Start Date
2026-10
Completion Date
2028-03
Last Updated
2026-10-14
Healthy Volunteers
Yes
Interventions
Fecal sample acquisition for Helicobacter pylori stool antigen test
Participants will be offered to perform Helicobacter pylori (H. pylori) Stool antigen test (SAT) for H. pylori infection identification. SAT may be used after eradication therapy to confirm H. pylori eradication success instead of 13C Urea Breath Test.
Upper endoscopy with biopsies
Upper endoscopy will be offered to participants with positive family history and/or alarm symptoms if such are identified (SAT and FIT negative individuals may not undergo questioning for the presence of alarm symptoms), provided a quality-assured endoscopic procedure has not been performed recently.
Colonoscopy with biopsies after bowel cleansing
Colonoscopy will be offered to participants with positive FIT results, or positive family history, provided a quality-assured endoscopic procedure has not been performed recently; or such participants will be managed within national CRC screening programme.
Helicobacter pylori eradication therapy
Helicobacter pylori eradication (antimicrobial) therapy offered to participants with Stool antigen test positive results. The recommended approach for first line treatment is bismuth quadruple therapy for 10-14 days, combined with a high-dose PPI BID. The recommended second line eradication medication: Levofloxacin-based quadruple/triple for 14 days plus high-dose PPI BID.
Fecal sample acquisition for Fecal Immunochemical test
Participants will be offered Fecal Immunochemical test for colorectal cancer screening.
Breath sample acquisition for 13C Urea Breath Test
13C Urea Breath test will be offered to participants at least 4 weeks after Helicobacter pylori eradication therapy end for eradication success control.